Angiotensin-converting enzyme 2 activation improves endothelial function

Hypertension

Volumn 61, Issue 6, 2013, Pages 1233-1238

  Fraga Silva, Rodrigo A ^a,d   Costa Fraga, Fabiana P ^a   Murça, Tatiane M ^c   Moraes, Patrícia L ^c   Martins Lima, Augusto ^a,b   Lautner, Roberto Q ^a,b   Castro, Carlos H ^c   Soares, Célia Maria A ^c   Borges, Clayton L ^c   Nadu, Ana Paula ^b   Oliveira, Marilene L ^b   Shenoy, Vinayak ^b   Katovich, Michael J ^b   Santos, Robson A S ^b   Raizada, Mohan K ^d   Ferreira, Anderson J ^c  

^a National Institute of Science and Technology in Nanobiopharmaceutics (NanoBiofar)   (Brazil)

^b Department of Physiology and Biophysics ^*  (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

angiotensin (1 7); diabetes mellitus; endothelium dysfunction; oxidative stress; renin angiotensin system

Indexed keywords

1 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 4 (HYDROXYMETHYL) 7 [[(4 METHYLPHENYL)SULFONYL]OXI] 9H XANTHONA 9; ACETYLCHOLINE; ANGIOTENSIN CONVERTING ENZYME 2; ENZYME ACTIVATOR; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CARDIOVASCULAR FUNCTION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; VASCULAR RING; VASODILATATION;

ANGIOTENSIN-(1-7); DIABETES MELLITUS; ENDOTHELIUM DYSFUNCTION; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

ANIMALS; AORTA, THORACIC; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REACTIVE OXYGEN SPECIES; VASODILATION; XANTHONES;

EID: 84878937766     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00627     Document Type: Article

References (32)

1. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995; 38: 87-104.
2. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens Suppl. 1996; 14: S83-S93. (Pubitemid 27051082)
3. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res. 2004; 37: 1263-1273. (Pubitemid 39172561)
4. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002; 89: 3A-9A; discussion 10A.
5. Ferreira AJ, Santos RAS. Cardiovascular actions of angiotensin-(1-7). Braz J Med Res. 2005; 38: 499-507.
6. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010; 55: 207-213.
7. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol. 2005; 90: 449-455. (Pubitemid 40980144)
8. Santos RAS, Simões e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003; 100: 8258-8263. (Pubitemid 36842532)
9. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): An update. Regul Pept. 2000; 91: 45-62.
10. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation. 2003; 108: 1679-1681. (Pubitemid 37243653)
11. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277: 14838-14843. (Pubitemid 34952556)
12. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian RX, Kimura S, Abe Y. Systemic and regional hemodynamic responses to tempol in Angiotensin II-infused hypertensive rats. Hypertension. 2001; 37: 77-83. (Pubitemid 32064243)
13. Wilson SK. Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat. Circ Res. 1990; 66: 722-734.
14. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res. 2011; 34: 154-160.
15. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension. 2005; 46: 948-952.
16. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008; 51: 574-580. (Pubitemid 351156450)
17. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008; 51: 1312-1317. (Pubitemid 351555943)
18. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011; 96: 287-294.
19. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179: 1048-1054.
20. Fraga-Silva RA, Sorg BS, Wankhede M, Dedeugd C, Jun JY, Baker MB, Li Y, Castellano RK, Katovich MJ, Raizada MK, Ferreira AJ. ACE2 activation promotes antithrombotic activity. Mol Med. 2010; 16: 210-215.
21. Murça TM, Moraes PL, Capuruço CA, Santos SH, Melo MB, Santos RA, Shenoy V, Katovich MJ, Raizada MK, Ferreira AJ. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetesinduced cardiac dysfunction. Regul Pept. 2012; 177: 107-115.
22. Murça TM, Almeida TC, Raizada MK, Ferreira AJ. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp Physiol. 2012; 97: 699-709.
23. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2 Hypertension. 2011; 57: 314-322.
24. Dong B, Zhang C, Feng JB, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008; 28: 1270-1276.
25. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS, Peterson MD, Backx PH, Penninger JM, Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008; 295: H1377-H1384.
26. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010; 59: 529-538.
27. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006; 6: 271-276. (Pubitemid 43670913)
28. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides. 2007; 28: 702-707. (Pubitemid 46204993)
29. Raffai G, Durand MJ, Lombard JH. Acute and chronic angiotensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol. 2011; 301: H1341-H1352.
30. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep. 2010; 12: 135-142.
31. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87: 840-844.
32. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008; 57: 1446-1454.